Taken together, our data strengthen the tumor suppressive function of TFF3 in retinoblastoma cells and emphasize TFF3’s downstream signaling components miR-34a and EMP1 as potential targets for adjuvant RB therapy and drug development strategies. The gene discussed is EMP1; the disease is neoplasm.